Immunome Inc.(IMNM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

IMNM Immunome Inc.

Market Closed 11-15 16:00:00 EST

9.91

-1.23

-11.09%

盘后10.37

+0.46+4.69%

19:15 EST

High11.19	Low9.64	Vol3.17M
Open11.19	D1 Closing11.14	Amplitude13.96%
Mkt Cap618.24M	Tradable Cap444.08M	Total Shares62.42M
T/O31.48M	T/O Rate7.06%	Tradable Shares44.83M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"IMNM","market":"US","secType":"STK","nameCN":"Immunome Inc.","latestPrice":9.905,"timestamp":1731704400000,"preClose":11.14,"halted":0,"volume":3166549,"hourTrading":{"tag":"盘后","latestPrice":10.37,"preClose":9.905,"latestTime":"19:15 EST","volume":6057,"amount":60755.043,"timestamp":1731716111710},"delay":0,"floatShares":44833526,"shares":62416845,"eps":-5.697009,"marketStatus":"Market Closed","change":-1.235,"latestTime":"11-15 16:00:00 EST","open":11.19,"high":11.19,"low":9.635,"amount":31484781.381668,"amplitude":0.139587,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-5.697009,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1731920400000},"marketStatusCode":7,"adr":0,"listingDate":1601611200000,"exchange":"NASDAQ","adjPreClose":11.14,"postHourTrading":{"tag":"盘后","latestPrice":10.37,"preClose":9.905,"latestTime":"19:15 EST","volume":6057,"amount":60755.043,"timestamp":1731716111710},"volumeRatio":4.58854575207245,"impliedVol":1.2058,"impliedVolPercentile":0.8532},"requestUrl":"/m/hq/s/IMNM","defaultTab":"news","newsList":[{"id":"2483322526","title":"Immunome Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags","url":"https://stock-news.laohu8.com/highlight/detail?id=2483322526","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483322526?lang=en_us&edition=fundamental","pubTime":"2024-11-15 19:28","pubTimestamp":1731670120,"startTime":"0","endTime":"0","summary":"NasdaqCM:IMNM Earnings and Revenue History November 15th 2024. All figures shown in the chart above are for the trailing 12 month  period. Revenue exceeded analyst estimates by 30%. Earnings per share  missed analyst estimates by 37%.Looking ahead, revenue is forecast to grow 65% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in the US.The company's shares are down 11% from a week ago.We don't want to rain on the parade too much, but we did also find 2 warning signs for Immunome that you need to be mindful of.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immunome-third-quarter-2024-earnings-112840707.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IMNM"],"gpt_icon":0},{"id":"2483874899","title":"Immunome Is Maintained at Overweight by Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2483874899","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483874899?lang=en_us&edition=fundamental","pubTime":"2024-11-14 20:35","pubTimestamp":1731587700,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMNM/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 14, 2024 07:35 ET (12:35 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMNM"],"gpt_icon":0},{"id":"2483176178","title":"Immunome Inc :  Piper Sandler Cuts Target Price to $21 From $23","url":"https://stock-news.laohu8.com/highlight/detail?id=2483176178","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483176178?lang=en_us&edition=fundamental","pubTime":"2024-11-14 14:46","pubTimestamp":1731566772,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nFWN3ML05V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4563","IMNM"],"gpt_icon":0},{"id":"2483089750","title":"Immunome Inc reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2483089750","media":"reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483089750?lang=en_us&edition=fundamental","pubTime":"2024-11-14 12:19","pubTimestamp":1731557991,"startTime":"0","endTime":"0","summary":"Immunome Inc reports results for the quarter ended September 30 - Earnings SummaryImmunome Inc IMNM.OQ reported a quarterly adjusted loss of 67 cents per share for the quarter ended September 30.  The","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nL8N3ML0CB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMNM"],"gpt_icon":0},{"id":"2483897475","title":"Immunome, Inc. Reports Q3 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2483897475","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483897475?lang=en_us&edition=fundamental","pubTime":"2024-11-14 12:19","pubTimestamp":1731557951,"startTime":"0","endTime":"0","summary":"Immunome, Inc. ( ($IMNM) ) has released its Q3 earnings. Here is a breakdown of the information Immunome, Inc. presented to its investors. Immunome...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/immunome-inc-reports-q3-2024-financial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/immunome-inc-reports-q3-2024-financial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4563","IMNM"],"gpt_icon":0},{"id":"2483860806","title":"Promising Growth Potential for Immunome: Buy Rating Backed by Strategic Acquisitions and Innovative Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2483860806","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483860806?lang=en_us&edition=fundamental","pubTime":"2024-11-14 09:15","pubTimestamp":1731546912,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Tyler Van Buren has reiterated their bullish stance on IMNM stock, giving a Buy rating on November 7. Tyler Van Buren has given hi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/promising-growth-potential-for-immunome-buy-rating-backed-by-strategic-acquisitions-and-innovative-pipeline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/promising-growth-potential-for-immunome-buy-rating-backed-by-strategic-acquisitions-and-innovative-pipeline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMNM"],"gpt_icon":0},{"id":"2483867857","title":"Immunome, Inc. (IMNM) Reports Q3 Loss, Misses Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2483867857","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483867857?lang=en_us&edition=fundamental","pubTime":"2024-11-14 06:15","pubTimestamp":1731536107,"startTime":"0","endTime":"0","summary":"Immunome, Inc.  came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.60. This compares to loss of $0.36 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -30%. A quarter ago, it was expected that this company would post a loss of $0.38 per share when it actually produced a loss of $0.49, delivering a surprise of -28.95%.Over the last four quarters, the company has surpassed consensus EPS estimates just once.Immunome , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $2.91 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 19.05%. This compares to year-ago revenues of $3.57 million. The company has topped consensus revenue estimates just once over the last four quarters.Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performan","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/64vRzkiY9LXGPrpW4r2GRQ--~B/aD00Njc7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/b95cfdd8768bc3c4620e666dbcb0b248","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/64vRzkiY9LXGPrpW4r2GRQ--~B/aD00Njc7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/b95cfdd8768bc3c4620e666dbcb0b248"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immunome-inc-imnm-reports-q3-221507159.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IMNM"],"gpt_icon":0},{"id":"2483534863","title":"Immunome Q3 EPS $(0.78) Misses $(0.56) Estimate, Sales $2.91M Beat $2.13M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2483534863","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483534863?lang=en_us&edition=fundamental","pubTime":"2024-11-14 05:22","pubTimestamp":1731532928,"startTime":"0","endTime":"0","summary":"Immunome (NASDAQ:IMNM) reported quarterly losses of $(0.78) per share which missed the analyst consensus estimate of $(0.56) by 39.29 percent. This is a 116.67 percent decrease over losses of $(0.36) per share from the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41955180/immunome-q3-eps-0-78-misses-0-56-estimate-sales-2-91m-beat-2-13m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Immunome Q3 EPS $(0.78) Misses $(0.56) Estimate, Sales $2.91M Beat $2.13M Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMNM"],"gpt_icon":0},{"id":"2483638438","title":"Immunome reports Q3 EPS (78c), consensus (56c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2483638438","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483638438?lang=en_us&edition=fundamental","pubTime":"2024-11-14 05:15","pubTimestamp":1731532520,"startTime":"0","endTime":"0","summary":"Reports Q3 revenue $2.91M, consensus $2.13M. “Immunome (IMNM) continues to advance its pipeline,” said Clay B. Siegall, Ph.D., President and Chief ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immunome-reports-q3-eps-78c-consensus-56c?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immunome-reports-q3-eps-78c-consensus-56c?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMNM"],"gpt_icon":0},{"id":"2483681918","title":"Immunome Inc: Current Cash Runway Is Expected to Extend Into 2026.","url":"https://stock-news.laohu8.com/highlight/detail?id=2483681918","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483681918?lang=en_us&edition=fundamental","pubTime":"2024-11-14 05:05","pubTimestamp":1731531904,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nTUA2G8KZF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4563","IMNM","BK4139"],"gpt_icon":0},{"id":"2483868569","title":"Immunome Q3 Operating Expenses USD 53.432 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2483868569","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483868569?lang=en_us&edition=fundamental","pubTime":"2024-11-14 05:05","pubTimestamp":1731531901,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nPLXD4087A:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4563","IMNM"],"gpt_icon":0},{"id":"2483868314","title":"Immunome Q3 Net Income USD -47.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2483868314","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483868314?lang=en_us&edition=fundamental","pubTime":"2024-11-14 05:05","pubTimestamp":1731531901,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nPLXD4087A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4563","BK4139","IMNM"],"gpt_icon":0},{"id":"2482089202","title":"ImmunityBio (IBRX) Reports Q3 Loss, Tops Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2482089202","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482089202?lang=en_us&edition=fundamental","pubTime":"2024-11-12 21:40","pubTimestamp":1731418803,"startTime":"0","endTime":"0","summary":"ImmunityBio  came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.19 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 22.22%. A quarter ago, it was expected that this immunotherapy company would post a loss of $0.17 per share when it actually produced a loss of $0.20, delivering a surprise of -17.65%.Over the last four quarters, the company has surpassed consensus EPS estimates just once.ImmunityBio , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $6.11 million for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 39.89%. This compares to year-ago revenues of $0.08 million. The company has topped consensus revenue estimates three times over the last four quarters.Investors should be mindful of the fact that the outlook for the industry can have a material im","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/bHsRpCKrGzzbaGHEolBtWw--~B/aD02MTg7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/023168c7ea091c342492be3899b280af","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/bHsRpCKrGzzbaGHEolBtWw--~B/aD02MTg7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/023168c7ea091c342492be3899b280af"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immunitybio-ibrx-reports-q3-loss-134003588.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IBRX","IMNM"],"gpt_icon":0},{"id":"2481059681","title":"Stephens Starts Immunome With Overweight Rating, $30 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2481059681","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481059681?lang=en_us&edition=fundamental","pubTime":"2024-11-08 21:57","pubTimestamp":1731074243,"startTime":"0","endTime":"0","summary":"Immunome (IMNM) has an average rating of buy and price targets ranging from $23 to $38, according to analysts polled by Capital IQ.(MT Newswires covers equity, commodity and economic research from maj","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IMNM"],"gpt_icon":0},{"id":"2481017912","title":"Immunome Initiated at Overweight by Stephens & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2481017912","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481017912?lang=en_us&edition=fundamental","pubTime":"2024-11-08 20:16","pubTimestamp":1731068160,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMNM/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 08, 2024 07:16 ET (12:16 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMNM"],"gpt_icon":0},{"id":"2481062745","title":"Immunome to Present at Guggenheim’s Inaugural Healthcare Innovation Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2481062745","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481062745?lang=en_us&edition=fundamental","pubTime":"2024-11-05 21:00","pubTimestamp":1730811600,"startTime":"0","endTime":"0","summary":"BOTHELL, Wash., November 05, 2024----Immunome, Inc. , a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, PhD, President and CEO of Immunome, will participate in a fireside chat at Guggenheim’s Inaugural Healthcare Innovation Conference on Wednesday, November 13th at 10:30am Eastern Time.Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company’s website at www.immunome.com. The webcast replay will be available after the conclusion of the live presentation for approximately 30 days.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/EWg5DmNToAilhD7oRzC73w--~B/aD0zMzQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/d229491180cb766e7ffcd1db762c0545","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/EWg5DmNToAilhD7oRzC73w--~B/aD0zMzQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/d229491180cb766e7ffcd1db762c0545"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immunome-present-guggenheim-inaugural-healthcare-130000964.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IMNM","BK4563","BK4137","HCSG","BK4139"],"gpt_icon":0},{"id":"2480852888","title":"Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2480852888","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480852888?lang=en_us&edition=fundamental","pubTime":"2024-11-02 04:05","pubTimestamp":1730491500,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241101:nTUA1KF3HM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4112","LU2210149790.SGD","BK4139","LU2210150020.SGD","BK4585","BK4563","LU2095319765.USD","BK4588","IE00BKPKM429.USD","NDAQ","IMNM","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2480852848","title":"Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2480852848","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480852848?lang=en_us&edition=fundamental","pubTime":"2024-11-02 04:05","pubTimestamp":1730491500,"startTime":"0","endTime":"0","summary":"BOTHELL, Wash., November 01, 2024----Immunome, Inc.  , a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on October 31, 2024, the Compensation Committee of the Company’s Board of Directors  granted inducement awards consisting of non-statutory stock options to purchase 378,800 shares of common stock to 14 new employees under the Company’s 2024 Inducement Plan. The Compensation Committee approved the stock options as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635.Each stock option has an exercise price equal to $11.47 per share, the Company’s closing sales price on October 31, 2024, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees’ continued service relatio","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/MFbLSHOVKSIuZcwuLjpBQw--~B/aD0zMzQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/a18dca83633bdfb4bd2b55a34cdffd74","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/MFbLSHOVKSIuZcwuLjpBQw--~B/aD0zMzQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/a18dca83633bdfb4bd2b55a34cdffd74"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immunome-reports-inducement-grants-under-200500394.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BKPKM429.USD",".IXIC","IE00B64PRP62.GBP","PSQ","QLD","BK4112","MNQmain","SQQQ","BK4585","QID","NQmain","LU2210150020.SGD","IE00B3QW5Z07.USD","LU2210149790.SGD","BK4139","NDAQ","TQQQ","BK4563","LU2095319765.USD","IE00BGHQF748.EUR","IMNM","BK4588"],"gpt_icon":1},{"id":"2479015514","title":"Immunome Advances with Strategic Asset Acquisition and Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2479015514","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479015514?lang=en_us&edition=fundamental","pubTime":"2024-10-29 20:30","pubTimestamp":1730205021,"startTime":"0","endTime":"0","summary":"Immunome ( ($IMNM) ) has shared an announcement. Immunome, Inc. has secured a pivotal asset purchase from Zentalis Pharmaceuticals, acquiring a lic...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/immunome-advances-with-strategic-asset-acquisition-and-agreement?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/immunome-advances-with-strategic-asset-acquisition-and-agreement?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4563","IMNM"],"gpt_icon":0},{"id":"2479401547","title":"Immunome presents preclinical data for IM-1021, ADC payload HC74","url":"https://stock-news.laohu8.com/highlight/detail?id=2479401547","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479401547?lang=en_us&edition=fundamental","pubTime":"2024-10-29 20:27","pubTimestamp":1730204872,"startTime":"0","endTime":"0","summary":"Immunome (IMNM) recently presented preclinical data for IM-1021 and the associated proprietary ADC payload HC74. The results were presented in a po...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immunome-presents-preclinical-data-for-im-1021-adc-payload-hc74?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immunome-presents-preclinical-data-for-im-1021-adc-payload-hc74?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4231","ADC","BK4563","BK4139","BK4080","IMNM"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.immunome.com","stockEarnings":[{"period":"1week","weight":-0.2369},{"period":"1month","weight":-0.1973},{"period":"3month","weight":-0.2679},{"period":"6month","weight":-0.2838},{"period":"1year","weight":0.2491},{"period":"ytd","weight":-0.0743}],"compareEarnings":[{"period":"1week","weight":-0.0208},{"period":"1month","weight":0.0059},{"period":"3month","weight":0.0567},{"period":"6month","weight":0.1063},{"period":"1year","weight":0.301},{"period":"ytd","weight":0.2324}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01 that targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.533663},{"month":2,"riseRate":0.5,"avgChangeRate":0.44569},{"month":3,"riseRate":0.5,"avgChangeRate":-0.042263},{"month":4,"riseRate":0,"avgChangeRate":-0.256118},{"month":5,"riseRate":0.75,"avgChangeRate":-0.00531},{"month":6,"riseRate":0.25,"avgChangeRate":-0.0071},{"month":7,"riseRate":0.5,"avgChangeRate":0.081647},{"month":8,"riseRate":0.25,"avgChangeRate":0.057093},{"month":9,"riseRate":0.5,"avgChangeRate":0.191692},{"month":10,"riseRate":0.25,"avgChangeRate":-0.054239},{"month":11,"riseRate":0,"avgChangeRate":-0.100303},{"month":12,"riseRate":0.25,"avgChangeRate":-0.126628}],"exchange":"NASDAQ","name":"Immunome Inc.","nameEN":"Immunome Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Immunome Inc.(IMNM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Immunome Inc.(IMNM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Immunome Inc.,IMNM,Immunome Inc.股票,Immunome Inc.股票老虎,Immunome Inc.股票老虎国际,Immunome Inc.行情,Immunome Inc.股票行情,Immunome Inc.股价,Immunome Inc.股市,Immunome Inc.股票价格,Immunome Inc.股票交易,Immunome Inc.股票购买,Immunome Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Immunome Inc.(IMNM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Immunome Inc.(IMNM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction